1 / 15

Implementing New Process Analytic Technologies: The underlying challenges PAT Subcommittee, June 12-13, 2002

Implementing New Process Analytic Technologies: The underlying challenges PAT Subcommittee, June 12-13, 2002. Justin O. Neway, Ph.D. Executive Vice President, Chief Science Officer Aegis Analytical Corporation http://www.aegiscorp.com. Outline. Background & information sources

dom
Download Presentation

Implementing New Process Analytic Technologies: The underlying challenges PAT Subcommittee, June 12-13, 2002

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Implementing New Process Analytic Technologies: The underlying challenges PAT Subcommittee, June 12-13, 2002 Justin O. Neway, Ph.D. Executive Vice President, Chief Science Officer Aegis Analytical Corporation http://www.aegiscorp.com

  2. Outline • Background & information sources • Perceived benefits of PAT implementation • What are the underlying challenges? • What can manufacturers do? • What can vendors do? • What can the FDA do?

  3. Background & Information Sources • ~15 Yrs in Process Development & Mfg. • Trained in Biochemistry & Microbiology • Worked in three Biotech/Pharma companies • Intimate with data problems in PD and manufacturing • ~5 Yrs with Aegis Analytical Corporation • Venture funded by GlaxoSmithKline, Merck, Aventis • Invited presentations to ~30 top Pharma & Biotech • Customer advisory panel & requirements consortia

  4. Benefits of PAT Implementation • Greater control of product uniformity • Improved safety, quality compliance • Shorter cycle times, batch release times • Cost savings, supply chain stability • Moves us towards parametric release • Cost savings, lower inventory • Moves us towards continuous operations • Improved control, significant capital adjustment What about today’s failure rates, compliance & yield problems?

  5. The Quality Compliance Challenge US Drug products are of high quality BUT: • Increasing trend towards manufacturing problems • Recalls, disruption of operations, drug shortages • Negative impact on New Drug Applications (NDA) • Low efficiency manufacturing and QA • Slow innovation and modernization Why do these problems occur? Janet Woodcock, M.D. FDA Science Board Presentation November 16. 2001

  6. Data-intensive Decision-making Identify and control Critical Process Parameters • Quality & regulatory compliance (GMP): • Parameter review for batch release • Setting defensible specifications • Investigation of atypical batches • Manufacturing process validation • Production trend analysis • Annual Product Reviews (APRs) • Process control (stability): • Shorten process start-up/scale-up times • Shorten trouble-shooting time/adverse trend reversal • Improve process stability, productivity & quality • Improve Return on Net Assets (RONA)

  7. The Real Manufacturing Data Environment The necessary data are in many separate locations Process yield & quality: discrete & replicate data LIMS PAT Instruments Process instrument measurements: discrete & continuous data Warehouse SCADA DCS PLCs Operators, times, volumes, quantities: discrete & replicate data Batch Records Material vendors, receive & release dates, equipment: discrete & replicate data ERP

  8. Decision-making “Inefficiencies” • Several weeks of manual data retrieval • Not a priority for corporate IT, multiple data sources • Spreadsheet madness • “Excel add-ins”, discrete, continuous & replicate data • Bewildering choice of inadequate software • Too many packages with too little real usability • Programming required from non-programmers • Antiquated ways to communicate results • Tables of highlighted numbers • Traditional 2D plots

  9. The World Around Us • Industry trends: • New instrumentation • Cheap data storage • Cheap computing power • Increased enforcement of GMP • Patent expirations • Industry consolidation, globalization The technology already exists to adequately deal with the “inefficiencies”

  10. PAT Data Analysis Technology Example

  11. Batch Release Technology Example - VPS Dissolution Rate Mixer Parameter Coating Parameter Dryer Parameter API Parameter

  12. The Advantages of PAT A Good Balance - Compliance and Economics • FDA: • Wants better compliance to ensure safety and efficacy • Wants better manufacturing efficiency to lower drug prices • Industry: • Wants to comply but lacks necessary software capabilities • Has been building the cost of failed batches into pricing • Wants to shorten cycle times to improve economics For this to work, the realties of the manufacturing data environment must also be dealt with

  13. What can we do? • Industry: • Boost manufacturing IT spending • Include mfg. users in budget prioritization • Implement underlying IT infrastructure needed for PAT • Vendors: • Make better software systems, work with industry • Be honest about software capabilities • Provide better training & support • FDA: • Continue emphasis on GMP compliance, outreach • Take opportunities to emphasize positive PAT economics

  14. What can we do? • PAT subcommittee: • Continue “safe harbor” policy implementation • Account for additional necessary mfg. infrastructure • Publicize compelling economic justification • Account for hard costs, soft costs and social costs • Sponsor industry/vendor working groups • Define needs, develop requirements, provide feedback

  15. Conclusions & Recommendations • PAT implementation, more difficult than expected • Requires much more than just new instrumentation • Challenges similar to other data-intensive decision-making “inefficiencies” • Poor data availability, inappropriate software systems • PAT – a unique economic incentive for quality compliance improvement • A good balance between compliance and improved economics • FDA - a catalyst for vendors, industry to work together • Gather data to show real world manufacturing software needs • Publicize the positive economics of PAT & quality compliance • Provide forums for industry/vendor collaboration

More Related